XmAb^® Candidate Discovery

Xencor is applying its XmAb® technology to create a portfolio of drug candidates for oncology, inflammation and autoimmune diseases. We are creating improved versions of antibodies that have shown strong potential for biological activity in humans. We believe that the enhancement of Fc-mediated effector function by application of XmAb® technologies will enable these antibodies to become successful drug candidates.

Each XmAb® candidate is designed with the following features:

• It is derived from an antibody with high selectivity for a target antigen against which antibodies have shown promising activity.
• It contains an Fc domain with amino acid substitutions that increase effector function to tailor drug performance for the desired clinical application, e.g. cytotoxic potency against tumor cells, or inhibition of immune cells for inflammatory disease.
• It contains a variable domain humanized (validated in humans) and optimized for high expression, solubility, and affinity using proprietary XmAb® Fv technology